Givinostat
Givinostat or gavinostat, aslo known as ITF2357, is a potent and orally active histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis.ITF2357 reduces cytokines and protects islet β cells in vivo and in vitro. ITF2357 decreases surface CXCR4 and CCR5 expression on CD4 (+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro.
Product Specifications
CAS Number
497833-27-9
Purity
>98% (HPLC)
Solubility
In Vitro: DMSO : 250 mg/mL (593.13 mM)
Smiles
O=C (OCC1=CC=C2C=C (CN (CC) CC) C=CC2=C1) NC3=CC=C (C (NO) =O) C=C3
Molecular Formula
C24H27N3O4
Molecular Weight
421.49
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(6- ((diethylamino) methyl) naphthalen-2-yl) methyl (4- (hydroxycarbamoyl) phenyl) carbamate
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FGFR, phosphorylated (Y766) (FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR, Fibroblast growth factor receptor 1, Basic fibroblast growth factor receptor 1, Fms-like tyrosine kinase 2, N-sam, Proto-oncogene c-Fgr, CD331) (FITC) discontinued
Lentiviral human SUGP1 shRNA (UAS) - Lentiviral human SUGP1 shRNA (UAS, iRFP) (100)
